Medically reviewed by Robert Burakoff, MD Crohn's disease is an inflammatory bowel disease that occurs when inflammation in ...

Learn about enteropathic arthritis, a common extra-intestinal symptom of Crohn’s disease that affects the joints.

Symptoms of Crohn’s disease may vary depending on the location of the condition in the gastrointestinal tract. Knowing what to look out for can help you and your doctor differentiate this ...

Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...

Patients with Crohn’s disease had high Epstein-Barr virus seropositivity in the preclinical period and at diagnosis of inflammatory bowel disease, according to results of a cohort study of military ...

The European Commission (EC) has approved ustekinumab for the treatment of moderately to severely active Crohn’s disease in ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an important role in the disease ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...

Take Steps is the Crohn’s & Colitis Foundation’s signature fundraising event. This year (2025), the event will take place at ...

Crohn’s disease and ulcerative colitis are both inflammatory bowel diseases with similar symptoms. However, some key differences include the areas they affect, diagnostic tools, and treatment plans.

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

Ustekinumab treatment may have better persistence than anti-TNF therapy as a second-line therapy in patients with Crohn's disease, along with improvements seen in clinical remission rates.